Cargando…

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Padilla, Mary, Kurosumi, Masafumi, Matsumoto, Hiroshi, Inoue, Kenichi, Horiguchi, Jun, Takeyoshi, Izumi, Oyama, Tetsunari, Ranger-Moore, Jim, Allred, D. Craig, Dennis, Eslie, Nitta, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937084/
https://www.ncbi.nlm.nih.gov/pubmed/27318853
http://dx.doi.org/10.1007/s10549-016-3856-2
_version_ 1782441648569974784
author Kurozumi, Sasagu
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
author_facet Kurozumi, Sasagu
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
author_sort Kurozumi, Sasagu
collection PubMed
description HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-016-3856-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4937084
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-49370842016-07-19 HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients Kurozumi, Sasagu Padilla, Mary Kurosumi, Masafumi Matsumoto, Hiroshi Inoue, Kenichi Horiguchi, Jun Takeyoshi, Izumi Oyama, Tetsunari Ranger-Moore, Jim Allred, D. Craig Dennis, Eslie Nitta, Hiroaki Breast Cancer Res Treat Clinical Trial HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s10549-016-3856-2) contains supplementary material, which is available to authorized users. Springer US 2016-06-18 2016 /pmc/articles/PMC4937084/ /pubmed/27318853 http://dx.doi.org/10.1007/s10549-016-3856-2 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Kurozumi, Sasagu
Padilla, Mary
Kurosumi, Masafumi
Matsumoto, Hiroshi
Inoue, Kenichi
Horiguchi, Jun
Takeyoshi, Izumi
Oyama, Tetsunari
Ranger-Moore, Jim
Allred, D. Craig
Dennis, Eslie
Nitta, Hiroaki
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title_full HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title_fullStr HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title_full_unstemmed HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title_short HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
title_sort her2 intratumoral heterogeneity analyses by concurrent her2 gene and protein assessment for the prognosis of her2 negative invasive breast cancer patients
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937084/
https://www.ncbi.nlm.nih.gov/pubmed/27318853
http://dx.doi.org/10.1007/s10549-016-3856-2
work_keys_str_mv AT kurozumisasagu her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT padillamary her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT kurosumimasafumi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT matsumotohiroshi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT inouekenichi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT horiguchijun her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT takeyoshiizumi her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT oyamatetsunari her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT rangermoorejim her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT allreddcraig her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT denniseslie her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients
AT nittahiroaki her2intratumoralheterogeneityanalysesbyconcurrenther2geneandproteinassessmentfortheprognosisofher2negativeinvasivebreastcancerpatients